Aarti Asnani MD
Director of Cardio-Oncology, Beth Israel Deaconess Medical Center
Join to View Full Profile
330 Brookline AveBoston, MA 02215
Phone+1 617-667-8800
Fax+1 617-632-7620
Dr. Asnani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Aarti Asnani is a Boston-based cardiologist specializing in cardio-oncology. She completed her medical education at Duke University School of Medicine and her residency, fellowship in cardiovascular disease, and post-doctoral fellowship at Massachusetts General Hospital. Dr. Asnani is currently Section Head of Cardio-Oncology at Beth Israel Deaconess Medical Center and serves as an attending physician at Massachusetts General Hospital. Her research includes publications on cardiotoxicity and the impact of cancer therapies on cardiovascular health, with work published in prominent journals such as Nature Cardiovascular Research and Cardiology Clinics.
Education & Training
Massachusetts General HospitalPost-Doctoral Fellowship, 2013 - 2017- Mass General Brigham/Massachusetts General HospitalFellowship, Cardiovascular Disease, 2011 - 2014
- Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
Duke University School of MedicineClass of 2008
Certifications & Licensure
MA State Medical License 2011 - 2028
American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
Publications & Presentations
PubMed
- Atorvastatin and left ventricular strain during anthracycline-based chemotherapy.Vencel Juhasz, Thiago Quinaglia, Zsofia D Drobni, Hannah K Gilman, Julius C Heemelaar
International Journal of Cardiology. 2026-07-01 - 25 citationsImmune checkpoint inhibitor-associated myocarditis: a novel risk score.John R Power, Charles Dolladille, Benay Ozbay, Adrien Procureur, Stephane Ederhy
European Heart Journal. 2026-03-05 - 1 citationsSelective Estrogen Receptor Degraders Induce Bradycardia by Modulating Nuclear Estrogen Signaling.Sandeep Basu, Andrea Nathalie Rosas Diaz, Jose Max Narvaez-Paliza, Casie Curtin, Shreya Kurella
JACC. Basic to Translational Science. 2026-02-01
Authored Content
- Ibrutinib-Associated CardiotoxicityJanuary 2020
- Ibrutinib-Associated CardiotoxicityJanuary 2020
Press Mentions
Corventum Announces IND Clearance for CVT-130, a First-in-Class Small Molecule for the Prevention of Anthracycline CardiotoxicityOctober 14th, 2025- Researchers ID Protein That May Protect the Heart During Certain Cancer Treatment RegimensDecember 27th, 2022
- Researchers ID Protein That May Protect the Heart During Certain Cancer Treatment RegimensDecember 27th, 2022
Grant Support
- Hemopexin as an Early Biomarker of Anthracycline Cardiac ToxicityBETH ISRAEL DEACONESS MEDICAL CENTER2022–2027
Professional Memberships
- Member
- Member
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
